RxDoctor Payments Data

Cayla Mays, NP

Nurse Practitioner · Muncie, INNPI 1255099503

Payments from drug & device makers

$7,026in general payments, 2019–2025

Across 401 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Amgen$1K
  • Johnson & Johnson$1K
  • Mallinckrodt Hospital Products Inc.$589
  • GSK$548
  • Novartis$541
  • plus $2K from 13 others

What the payments were for

  • Food & beverage$6,45492%
  • Education$5728%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,026 in reported general payments places this provider in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

See all nurse practitioner providers in Indiana

Medicare billing

Part B allowed, 2024
$769,867
Medicare patients
316
Services billed
40,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab117$839,229
Orencia ClickjectAbatacept131$728,698
Enbrel SureclickEtanercept80$581,286
Skyrizi PenRisankizumab-Rzaa19$397,944
BenlystaBelimumab56$280,105
Cosentyx Sensoready PenSecukinumab26$192,769
Humira(Cf)Adalimumab26$176,607
OtezlaApremilast30$156,670
Xeljanz XrTofacitinib Citrate25$142,644
SimponiGolimumab20$129,788
Taltz AutoinjectorIxekizumab19$129,017
Humira PenAdalimumab13$87,484
OrenciaAbatacept15$85,613
KevzaraSarilumab19$80,988
ActemraTocilizumab12$34,146

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBenlysta$548$280,10556 claims
AbbVieHumira(Cf)$1,161$176,60726 claims
AmgenOtezla$1,097$156,67030 claims
Johnson & JohnsonSimponi$1,011$129,78820 claims
E.r. Squibb & Sons, L.L.C.Orencia$158$85,61315 claims
SanofiKevzara$49$80,98819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 nurse practitioner providers in Indiana.

Other nurse practitioner in Muncie

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →